Bristol-Myers Squibb Co. (BMY) Social Stream
Bristol Myers Squibb Co (BMY) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering Bristol Myers Squibb Co.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Current Price||Upside Potential|
The Trend in the Analyst Price Target
Over the past 43 weeks, BMY's average price target has gone down $2.97.
Over the past 51 weeks, BMY's average upside potential has been 14.94%.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Share Price||Upside Potential|
BMY Broker Recommendations Summary
|Average Broker Rating||Strong Buy||Buy||Hold||Sell||Strong Sell||Analysts Issuing Recs|
The Trend in the Broker Recommendations
BMY's average broker recommendation rating worsened by 0.1 over the prior 15 months.
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for BMY as an investment opportunity.
- Bristol Myers Squibb Co's upside potential (average analyst target price relative to current price) is greater than 102.53% of all US stocks.
- BMY has a higher number of analysts covering the stock than 703.95% of Pharmaceutical Products stocks.
- To contextualize these metrics, consider that out of Pharmaceutical Products stocks, Bristol Myers Squibb Co's variance in analysts' estimates is lower than -42.18% of them.
- In terms of how Bristol Myers Squibb Co fares relative to Pharmaceutical Products stocks, note that its average analyst price target is greater than 639.91% of that group.
Is BMY a Buy, Hold or Sell? See the POWR Ratings now!